ArticleBiomedical engineering letters2025
Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment.
Article in Biomedical engineering letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hair loss affects significant social and psychological well-being issues of the person. Thus, various drugs, ingredients, and technologies are being developed to overcome it. Minoxidil (MXD) is a representative hair loss treatment drug because it suppresses the production of dihydrotestosterone and induces vasodilation. However, since MXD has various side effects when used orally, it is more desirable to use it topically. In this work, we disclosed a new polymeric formulation (MXD@CP) based on citric acid (CA) dimethylsiloxane polymer (CP) for the effective transdermal delivery of MXD. Methods: The polymer that induced ring-opening polymerization based on CA was named CA-siloxane polymer (CP). After CP synthesis, MXD was loaded onto CP to form MXD@CP. The formed MXD@CP was confirmed to have efficacy as a transdermal delivery system through various material property analyses and biotoxicity and therapeutic efficacy analyses. Results: In these results, CP stably loaded MXD up to 5%, a concentration used in clinical practice, and showed higher hair growth efficacy and hair follicle formation efficacy compared to MXD@PBS. Conclusion: In the animal study, MXD@CP showed a superior hair growth effect which suggests its potential as a next-generation hair loss treatment agent. Supplementary Information: The online version contains supplementary material available at 10.1007/s13534-025-00460-0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.